Related references
Note: Only part of the references are listed.Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Paolo A. A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Ines Pires da Silva et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade
Annette Paschen et al.
ANNUAL REVIEW OF CANCER BIOLOGY (2022)
Deciphering radiological stable disease to immune checkpoint inhibitors
J. Luo et al.
ANNALS OF ONCOLOGY (2022)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung Chul Cho et al.
LANCET ONCOLOGY (2022)
Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
J. C-H. Yang et al.
ANNALS OF ONCOLOGY (2021)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Lewis Au et al.
CANCER CELL (2021)
DREAMseq (Doublet Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano et al.
CLINICAL CANCER RESEARCH (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
B. Besse et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2021)
PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
Mohamad E. Allaf et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
Matthew D. Hellmann et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma
Teresa Amaral et al.
CANCERS (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
Moshe C. Ornstein et al.
LANCET ONCOLOGY (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Song Ee Park et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)
Ari M. Vanderwalde et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Mark D. Turner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CXC chemokine ligand 9/monokine induced by IFN-γ production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors
Anton V. Gorbachev et al.
JOURNAL OF IMMUNOLOGY (2007)